Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Artificial Intelligence (AI) In Clinical Trials Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The artificial intelligence (AI) in clinical trials market size has experienced significant expansion in recent years. It is projected to grow from $10.11 billion in 2025 to $14.11 billion in 2026, at a compound annual growth rate (CAGR) of 39.6%. The growth observed in the past can be attributed to factors such as rising clinical trial failure rates, increased research and development (R&D) investment by pharmaceutical companies, an expansion in clinical data volumes, the necessity for more rapid drug approvals, and the inherent inefficiencies found in traditional trial processes.
The artificial intelligence (AI) in clinical trials market size is projected to experience substantial growth in the coming years. This market is anticipated to reach $47.22 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 35.3%. Factors driving this expansion during the forecast period include the increasing adoption of decentralized clinical trials, greater regulatory approval of AI instruments, advancements in precision medicine research, the need for more economical trials, and innovations in healthcare analytics. Key developments expected in this period encompass AI-powered trial design optimization, predictive models for patient enrollment, data-driven approaches to site selection, automated analysis of clinical outcomes, and platforms for adaptive trial execution.
Get A Free Sample Report With In-Depth Market Insights:
Artificial Intelligence (AI) In Clinical Trials Market Demand Drivers: What’s Powering Industry Growth?
The increasing necessity to control expenditures in clinical trials is projected to fuel the expansion of artificial intelligence within the clinical trial market moving ahead. Clinical trials are defined as research investigations conducted to evaluate medical, surgical, or behavioral interventions on individuals, with associated costs encompassing both research expenses and patient care expenditures. The processes involved in drug development and other clinical trials are inherently expensive; however, artificial intelligence offers solutions for enhanced drug discovery, the creation of more effectively designed and safer clinical trials, and superior patient outcomes, all at reduced expenses. For example, in February 2023, Genetic Engineering and Biotechnology News, a US-based platform delivering current information on genetic engineering and biotechnology, reported that the expense of developing a new drug among the leading 20 global biopharmaceutical firms escalated by 15%, increasing from $298 million in 2022 to an estimated $2.3 billion in 2023, encompassing costs from drug development through clinical trials. Moreover, a January 2023 report from the National Bureau of Economic Research (NBER), a US-based non-profit economic research organization, projected that integrating AI over the subsequent five years could yield significant cost reductions in healthcare, potentially saving 5 to 10% of healthcare spending, which translates to roughly $200 billion to $360 billion in yearly savings. Consequently, the intensifying demand to manage clinical trial expenditures will fuel the advancement of artificial intelligence in the clinical trial market.
Artificial Intelligence (AI) In Clinical Trials Market Segment Outlook: Which Categories Are Growing Fastest?
The artificial intelligence (AI) in clinical trials market covered in this report is segmented –
1) By Offering: Software, Services
2) By Process: Trial Design, Patient Selection, Site Selection, Patient Monitoring
3) By Application: Oncology, Neurological Disease And Condition, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Immunology Disease, Other Applications
4) By End-User: Pharmaceutical And Biotechnology Company, Contract Research Organizations, Other End-Users
Subsegments:
1) By Software: AI-driven Analytics Platforms, Data Management Tools, Patient Recruitment Solutions, Predictive Modeling Software
2) By Services: Consulting Services, Data Annotation And Labeling Services, Custom AI Model Development, Implementation And Integration Services
Artificial Intelligence (AI) In Clinical Trials Market Innovation Trends: What Developments Are Reshaping The Industry?
Key companies active in the artificial intelligence in clinical trials market are concentrating on developing innovative technologies, including AI feasibility and recruitment platforms. These platforms are tools or systems that utilize artificial intelligence (AI) to evaluate the viability and potential success of clinical trials, while also supporting the effective recruitment of appropriate participants. For instance, in June 2023, a US-based research provider company unveiled ‘ObjectiveScreen’. This AI-powered feasibility and recruitment platform works to boost clinical trial performance and results by enhancing patient identification, prequalification, and retention procedures. ObjectiveScreen establishes direct connectivity between clinical trial sites and the electronic health records (EHRs) of patients. The AI platform encourages patient engagement by simplifying and streamlining appointment scheduling and communication processes.
Artificial Intelligence (AI) In Clinical Trials Market Leading Companies And Competitive Benchmarking
Major companies operating in the artificial intelligence (AI) in clinical trials market are Medable Inc.; PathAI inc.; Saama Technologies Inc.; TriNetX LLC; SymphonyAI Summit Inc.; Aktana; Nference Inc.; Insilico Medicine Inc.; Vineti Inc.; Innoplexus AG; Healx; AiCure Inc.; MEDIAN Technologies SA; Owkin Inc.; Science 37; Ardigen SA; Cyft Inc.; Unlearn.AI Inc.; Mendel AI; Deep Lens Inc.; Antidote Technologies Inc.; Arterys Inc.; Euretos BV; Halo Health Systems Inc.; Trials.AI Inc.; Transparency Life Sciences; BioAge Labs Inc.; Wave Life Sciences Ltd.; BioSymetrics Inc.
View The Full Artificial Intelligence (AI) In Clinical Trials Market Report:
Artificial Intelligence (AI) In Clinical Trials Market Top Region By Revenue And Market Share
North America was the largest region in the artificial intelligence (AI) in clinical trials market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) in clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.
